AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30123523 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol infusion (targeted to heart rate 80-90/min)
Number of subjects: 7
Study 30123523 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol infusion
Number of subjects: 7
Study 30123673 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg twice daily during the first 3 cycles of VCD induction therapy
Number of subjects: 58
Study 30123673 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet twice daily during the first 3 cycles of VCD induction therapy
Number of subjects: 58
Study 30123846 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (AC)
Number of subjects: 150
Study 30123846 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal formulation (HB)
Number of subjects: 150
Study 30123846 — intervention group
Group type: COMPARATOR
Intervention: Artificial tears (AT)
Number of subjects: 150
Study 30123935 — intervention group
Group type: EXPERIMENTAL
Intervention: Amyloid PET imaging
Number of subjects: 97
Study 30124008 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) injection of bone marrow derived mesenchymal stromal cells (BM-MSCs), n=6
Number of subjects: 14
Study 30124008 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal (IT) injection of bone marrow derived mesenchymal stromal cells (BM-MSCs), n=8
Number of subjects: 14
Study 30124502 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided BPB
Number of subjects: 15
Study 30124757 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition Literacy (NL)
Number of subjects: 320
Study 30124757 — intervention group
Group type: EXPERIMENTAL
Intervention: Black participants
Number of subjects: 320
Study 30124757 — intervention group
Group type: EXPERIMENTAL
Intervention: Education level
Number of subjects: 320
Study 30124798 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioband procedure
Number of subjects: 60
Study 30124844 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin
Number of subjects: 31
Study 30124844 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid
Number of subjects: 31
Study 30124844 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Number of subjects: 31
Study 30124844 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethambutol
Number of subjects: 31
Study 30124893 — intervention group
Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acids (MUFAs)
Number of subjects: 1228
Study 30124893 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyunsaturated fatty acids (PUFAs)
Number of subjects: 1228
Study 30124893 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated fatty acids (SFAs)
Number of subjects: 1228
Study 30124893 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans fatty acids (TFAs)
Number of subjects: 1228
Study 30124893 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 1228
Study 30124893 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-6 linoleic acid
Number of subjects: 1228
Study 30124968 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance cholangiopancreatography (MRCP) screening
Number of subjects: 54
Study 30125215 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating tumor DNA (ctDNA) levels before therapy
Number of subjects: 217
Study 30125215 — intervention group
Group type: EXPERIMENTAL
Intervention: Early molecular response (EMR) after one cycle of therapy
Number of subjects: 217
Study 30125215 — intervention group
Group type: EXPERIMENTAL
Intervention: Major molecular response (MMR) after two cycles of therapy
Number of subjects: 217
Study 30125215 — intervention group
Group type: EXPERIMENTAL
Intervention: Early molecular response (EMR) in salvage therapy
Number of subjects: 217
Study 30125215 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA levels and molecular responses
Number of subjects: 217
Study 30126352 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial Spin Labeling (ASL) perfusion and Diffusion Weighted Imaging (DWI)
Number of subjects: 116
Study 30126352 — intervention group
Group type: COMPARATOR
Intervention: Diffusion Weighted Imaging (DWI) without ASL
Number of subjects: 116
Study 30126352 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion Weighted Imaging (DWI) with ASL
Number of subjects: 116
Study 30126352 — intervention group
Group type: COMPARATOR
Intervention: Susceptibility Weighted Imaging (SWI)
Number of subjects: 116
Study 30126361 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for MRB colonization using swabs from the nose, throat, and rectum.
Number of subjects: 10000
Study 30126361 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of a clinical tool for identifying risk groups for MRB colonization.
Number of subjects: 10000
Study 30126395 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous knee/hip injury
Number of subjects: 2661
Study 30126395 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of osteoarthritis
Number of subjects: 2661
Study 30126395 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BMI
Number of subjects: 2661
Study 30126395 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee/hip injuries and surgeries
Number of subjects: 2661
Study 30126395 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent knee/hip pain
Number of subjects: 2661
Study 30126395 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint injury and overweight during early adulthood
Number of subjects: 2661
Study 30126401 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective measurements including lung function and quantitative assessment of airway inflammation and exhaled breath, peripheral blood, skin, nasal, pharyngeal, and nasopharyngeal swabs, nasal secretions, primary nasal epithelial cells, and induced sputum.
Number of subjects: 0
Study 30126401 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized questionnaires and structured interviews, telephone interviews.
Number of subjects: 0
Study 30126401 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular objective measurements and biomaterial collection.
Number of subjects: 0
Study 30126440 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR) in 5 fractions
Number of subjects: 90
Study 30126440 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR) in 3 fractions
Number of subjects: 90
Study 30126440 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR) in 1 fraction
Number of subjects: 90
Study 30126674 — intervention group
Group type: EXPERIMENTAL
Intervention: Pfs25 VLP-FhCMB vaccine combined with Alhydrogel® adjuvant
Number of subjects: 0
Study 30126674 — intervention group
Group type: EXPERIMENTAL
Intervention: Pfs25 VLP-FhCMB vaccine
Number of subjects: 0
Study 30126709 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-like growth factor-1 (IGF-1)
Number of subjects: 197
Study 30126709 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional support
Number of subjects: 197
Study 30126765 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide 1L treatment (chemo-naive)
Number of subjects: 117
Study 30126765 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide 2L treatment (post-docetaxel or -abiraterone)
Number of subjects: 117
Study 30126765 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide 3L or 4L treatment
Number of subjects: 117
Study 30126765 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide (overall)
Number of subjects: 117
Study 30126765 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide (fatigue incidence)
Number of subjects: 117
Study 30126765 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide 3L or 4L treatment (fatigue)
Number of subjects: 117
Study 30126861 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (70 mg/m2)
Number of subjects: 112
Study 30126861 — intervention group
Group type: COMPARATOR
Intervention: Irinotecan
Number of subjects: 112
Study 30126861 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Number of subjects: 112
Study 30126891 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted medication reconciliation quality improvement intervention
Number of subjects: 1648
Study 30126891 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1648
Study 30126931 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative drop in platelets >25% at landmark
Number of subjects: 807
Study 30126931 — intervention group
Group type: COMPARATOR
Intervention: Relative drop in platelets ≤25% at landmark
Number of subjects: 807
Study 30126953 — intervention group
Group type: EXPERIMENTAL
Intervention: ETX2514SUL (combination of ETX2514 and sulbactam)
Number of subjects: 0
Study 30127037 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical chemistry score (CCS)
Number of subjects: 0
Study 30127037 — intervention group
Group type: COMPARATOR
Intervention: High-sensitivity cardiac troponin I (hs-cTnI)
Number of subjects: 0
Study 30127037 — intervention group
Group type: COMPARATOR
Intervention: High-sensitivity cardiac troponin T (hs-cTnT)
Number of subjects: 0
Study 30127621 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of oral osimertinib, oral temozolomide, intrathecal cytarabine, and whole-brain radiation therapy
Number of subjects: 1
Study 30127664 — intervention group
Group type: EXPERIMENTAL
Intervention: Diary written by a close relative of a critically ill patient, with guidance from ICU nurses.
Number of subjects: 200
Study 30127805 — intervention group
Group type: EXPERIMENTAL
Intervention: Icatibant
Number of subjects: 73
Study 30128164 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised telemedicine cognitive behavioural therapy (CBT)-based intervention
Number of subjects: 40
Study 30128164 — intervention group
Group type: COMPARATOR
Intervention: Self-guided web-based relaxation programme
Number of subjects: 40
Study 30128316 — intervention group
Group type: EXPERIMENTAL
Intervention: Drisapersen 6 mg/kg/week for 24 weeks
Number of subjects: 51
Study 30128316 — intervention group
Group type: EXPERIMENTAL
Intervention: Drisapersen 3 mg/kg/week for 24 weeks
Number of subjects: 51
Study 30128316 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 30128496 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo confocal microscopy (IVCM)
Number of subjects: 30
Study 30128496 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser scanning confocal microscopy (LSCM)
Number of subjects: 30
Study 30128496 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide-field imaging
Number of subjects: 30
Study 30128502 — intervention group
Group type: EXPERIMENTAL
Intervention: PVX-410 vaccine (0.4 mg total, 0.1 mg/peptide, n=3) or (0.8 mg total, 0.2 mg/peptide, n=9) biweekly via subcutaneous injection, plus 0.5 mL (1 mg) poly-ICLC (2 mg/mL) via intramuscular injection with each dose.
Number of subjects: 22
Study 30128502 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of PVX-410 vaccine with lenalidomide (25 mg orally daily for three 21-day cycles, n=10).
Number of subjects: 22
Study 30128502 — intervention group
Group type: COMPARATOR
Intervention: PVX-410 vaccine alone (monotherapy).
Number of subjects: 22
Study 30128591 — intervention group
Group type: EXPERIMENTAL
Intervention: Infectious purpura fulminans
Number of subjects: 306
Study 30128605 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal decorin 200 μg
Number of subjects: 12
Study 30128605 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal decorin 400 μg
Number of subjects: 12
Study 30128605 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal decorin (both dosages)
Number of subjects: 12
Study 30129045 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab maintenance (RM) after R-CHOP-based induction therapy
Number of subjects: 0
Study 30129045 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP-based induction therapy
Number of subjects: 0
Study 30130439 — intervention group
Group type: EXPERIMENTAL
Intervention: Rozanolixizumab (30 mg/kg IV single dose)
Number of subjects: 0
Study 30130439 — intervention group
Group type: EXPERIMENTAL
Intervention: Rozanolixizumab (initial 30 mg/kg loading dose; 5 mg/kg daily thereafter)
Number of subjects: 0
Study 30130439 — intervention group
Group type: EXPERIMENTAL
Intervention: Rozanolixizumab (≤ 150 mg/kg every 3 days, subcutaneous and IV)
Number of subjects: 0
Study 30131059 — intervention group
Group type: EXPERIMENTAL
Intervention: Inconsistently moderate drinkers (males: 1-168 g ethanol/week; females: 1-112 g ethanol/week)
Number of subjects: 35132
Study 30131059 — intervention group
Group type: EXPERIMENTAL
Intervention: Former drinkers
Number of subjects: 35132
Study 30131059 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent non-drinkers
Number of subjects: 35132
Study 30131059 — intervention group
Group type: COMPARATOR
Intervention: Consistently heavy drinkers
Number of subjects: 35132
Study 30131059 — intervention group
Group type: COMPARATOR
Intervention: Inconsistently heavy drinkers
Number of subjects: 35132
Study 30131390 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-surgery (after partial pancreatectomy)
Number of subjects: 0
Study 30131390 — intervention group
Group type: COMPARATOR
Intervention: Pre-surgery (before partial pancreatectomy)
Number of subjects: 0
Study 30131727 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 30131748 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational Therapy
Number of subjects: 0
Study 30131748 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30132694 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin
Number of subjects: 39
Study 30132694 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 39
Study 30132694 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Number of subjects: 39
Study 30132694 — intervention group
Group type: COMPARATOR
Intervention: Clinical observation
Number of subjects: 39
Study 30132969 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher fetal hemoglobin (HbF) levels
Number of subjects: 57
Study 30132969 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher hemoglobin (Hb) concentration
Number of subjects: 57
Study 30132969 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite endpoint of severe clinical events
Number of subjects: 57
Study 30132969 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization due to febrile illness
Number of subjects: 57
Study 30133164 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy for 12 weeks
Number of subjects: 31
Study 30134122 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified protein derivative-treated sarcoidosis PBMCs
Number of subjects: 11
Study 30134122 — intervention group
Group type: COMPARATOR
Intervention: Control PBMCs
Number of subjects: 11
Study 30134131 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (1 mg/kg) plus Ipilimumab (3 mg/kg) every 3 weeks for up to four doses, followed by Nivolumab (3 mg/kg) every 2 weeks until progression or unacceptable toxic effects
Number of subjects: 94
Study 30134131 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (1 mg/kg) plus Ipilimumab (3 mg/kg)
Number of subjects: 94
Study 30134131 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab combined with Ipilimumab
Number of subjects: 94
Study 30134368 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal astigmatism in PACD patients
Number of subjects: 808
Study 30134368 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal astigmatism in primary angle closure suspect (PACS)
Number of subjects: 808
Study 30134368 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal astigmatism in primary angle closure (PAC)
Number of subjects: 808
Study 30134368 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal astigmatism in primary angle closure glaucoma (PACG)
Number of subjects: 808
Study 30134368 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal astigmatism in PACD after matching
Number of subjects: 808
Study 30134368 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-related effects on ATR astigmatism
Number of subjects: 808
Study 30134969 — intervention group
Group type: EXPERIMENTAL
Intervention: Accepted applications
Number of subjects: 201
Study 30134969 — intervention group
Group type: COMPARATOR
Intervention: Not Accepted applications
Number of subjects: 201
Study 30135031 — intervention group
Group type: COMPARATOR
Intervention: Poor Metabolizers (PM)
Number of subjects: 2558
Study 30135031 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19 groups
Number of subjects: 2558
Study 30135052 — intervention group
Group type: EXPERIMENTAL
Intervention: HITSystem eHealth intervention
Number of subjects: 17
Study 30135052 — intervention group
Group type: COMPARATOR
Intervention: Standard EID
Number of subjects: 17
Study 30135256 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalized digit-span forward (d-sf) scores in participants with nmDMD mutations downstream of exon 30
Number of subjects: 169
Study 30135256 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalized digit-span forward (d-sf) scores in participants with nmDMD mutations downstream of exon 45
Number of subjects: 169
Study 30135256 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalized digit-span forward (d-sf) scores in participants with nmDMD mutations downstream of exon 63
Number of subjects: 169
Study 30135747 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion Group (DG)
Number of subjects: 84
Study 30135747 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally Guided (MSG)
Number of subjects: 84
Study 30135747 — intervention group
Group type: COMPARATOR
Intervention: Wait List Control (WLC)
Number of subjects: 84
Study 30135755 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized cognitive behavioural therapy (CCBT) with Internet Support Group (ISG)
Number of subjects: 0
Study 30135755 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized cognitive behavioural therapy (CCBT) without Internet Support Group (ISG)
Number of subjects: 0
Study 30135755 — intervention group
Group type: COMPARATOR
Intervention: Traditional face-to-face psychotherapies
Number of subjects: 0
Study 30135764 — intervention group
Group type: EXPERIMENTAL
Intervention: Unguided internet-delivered cognitive-behavioral therapy for insomnia (ICBTi)
Number of subjects: 0
Study 30135764 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (Cognitive-behavioral therapy for insomnia)
Number of subjects: 0
Study 30137238 — intervention group
Group type: EXPERIMENTAL
Intervention: TFV disoproxil fumarate (TDF)-based therapy
Number of subjects: 532
Study 30137350 — intervention group
Group type: EXPERIMENTAL
Intervention: Objectively measured physical activity (PA) levels
Number of subjects: 130
Study 30137396 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-for-length z score (zWFL) at birth
Number of subjects: 630
Study 30137396 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain from 0 to 2 years
Number of subjects: 630
Study 30137396 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood adiposity
Number of subjects: 630
Study 30137396 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeostasis model assessment for insulin resistance
Number of subjects: 630
Study 30137397 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenal venous sampling (AVS)
Number of subjects: 39
Study 30137406 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher bioavailable testosterone, free testosterone, dehydroepiandrosterone (DHEA), and lower sex hormone-binding globulin (SHBG) levels
Number of subjects: 2371
Study 30137406 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher total testosterone in women
Number of subjects: 2371
Study 30137406 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher estradiol in men
Number of subjects: 2371
Study 30137406 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher total testosterone, bioavailable testosterone, free testosterone, DHEA, and lower estradiol and SHBG in women longitudinally
Number of subjects: 2371
Study 30137406 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher free testosterone and estradiol in men longitudinally
Number of subjects: 2371
Study 30137477 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-d models
Number of subjects: 7
Study 30137477 — intervention group
Group type: COMPARATOR
Intervention: Long-term full models
Number of subjects: 7
Study 30137523 — intervention group
Group type: EXPERIMENTAL
Intervention: Skeletal muscle transcriptome analysis in Malays
Number of subjects: 156
Study 30137523 — intervention group
Group type: COMPARATOR
Intervention: Skeletal muscle transcriptome analysis in Chinese
Number of subjects: 156
Study 30137523 — intervention group
Group type: COMPARATOR
Intervention: Skeletal muscle transcriptome analysis in Asian-Indians
Number of subjects: 156
Study 30137523 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene clusters analysis
Number of subjects: 156
Study 30137527 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioactive iodine (RAI) treatment
Number of subjects: 279
Study 30137598 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal knowledge of childhood sleep (measured by Parents' Sleep Knowledge Inventory)
Number of subjects: 112
Study 30137598 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily sleep duration and variability measured by wrist actigraphy
Number of subjects: 112
Study 30137598 — intervention group
Group type: EXPERIMENTAL
Intervention: CSHQ sleep disturbance scores
Number of subjects: 112
Study 30138022 — intervention group
Group type: EXPERIMENTAL
Intervention: brief cognitive-behavioral therapy (bCBT)
Number of subjects: 132
Study 30138170 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen Reserve Index (ORi) measured noninvasively by multiwavelength pulse co-oximetry
Number of subjects: 20
Study 30138170 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen Reserve Index (ORi) trending ability
Number of subjects: 20
Study 30138170 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction of hypoxia (PaO2 <100 mm Hg) using ORi
Number of subjects: 20
Study 30138228 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation intervention (12-week duration)
Number of subjects: 31
Study 30138228 — intervention group
Group type: COMPARATOR
Intervention: Typical walking
Number of subjects: 31
Study 30138228 — intervention group
Group type: EXPERIMENTAL
Intervention: Challenging walking tasks (obstacles and dual-task walking)
Number of subjects: 31